Intellia Therapeutics Inc (NASDAQ:NTLA)’s share price dropped 10.6% on Friday . The stock traded as low as $13.81 and last traded at $13.86, approximately 981,501 shares were traded during mid-day trading. An increase of 57% from the average daily volume of 625,906 shares. The stock had previously closed at $15.51.
A number of equities research analysts recently issued reports on NTLA shares. BidaskClub upgraded Intellia Therapeutics from a “sell” rating to a “hold” rating in a research report on Thursday, February 6th. Wedbush lowered Intellia Therapeutics from an “outperform” rating to a “neutral” rating and dropped their price objective for the company from $21.00 to $16.00 in a research note on Friday. ValuEngine cut Intellia Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, November 5th. Raymond James upgraded Intellia Therapeutics from a “market perform” rating to an “outperform” rating and set a $24.00 target price on the stock in a research note on Friday, November 1st. Finally, Zacks Investment Research cut Intellia Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and four have issued a buy rating to the company. Intellia Therapeutics currently has an average rating of “Hold” and an average target price of $25.25.
The company has a debt-to-equity ratio of 0.05, a quick ratio of 7.89 and a current ratio of 7.89. The firm has a market cap of $761.58 million, a PE ratio of -7.04 and a beta of 2.82. The stock’s 50 day simple moving average is $14.31 and its 200 day simple moving average is $14.56.
Intellia Therapeutics Company Profile (NASDAQ:NTLA)
Intellia Therapeutics, Inc, a genome editing company, focuses on the development of therapeutics utilizing a biological tool known as the CRISPR/Cas9 system. The company develops in vivo programs focused on liver diseases, including transthyretin amyloidosis, alpha-1 antitrypsin deficiency, and primary hyperoxaluria.
Featured Story: What is required to own or exchange cryptocurrency?
Receive News & Ratings for Intellia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.